Table 2.
Susceptible proportions of Enterobacteriaceae (coliforms) in each infection group.
| Susceptible proportion (%) | |||
|---|---|---|---|
| LRTI (n = 34) | SSTI (n = 23) | UTI (n = 33) | |
| Ciprofloxacin | 14.7 | 13.0 | 15.2 |
| Co-trimoxazole | ∗∗ | 26.1 | 30.3 |
| Co-amoxiclav | 2.9 | 4.3 | 9.1 |
| Gentamycin | 73.5 | 30.4 | 48.5 |
| Cefuroxime | 2.9 | 13 | 18.2 |
| Amikacin | 73.5 | 65.2 | 81.8 |
| Imipenem/meropenem | 47.1 | 60.9 | 60.6 |
| Piperacillin-tazobactam | 23.5 | 52.2 | 30.3 |
| Ticarcillin-clavulanic acid | 11.8 | ∗∗ | 15.2 |
| Cefotaxime | 14.2 | 13.0 | 18.2 |
| Aztreonam | 17.6 | 13.0 | 27.3 |
| Nitrofurantoin | ∗∗ | ∗∗ | 48.5 |
| Nalidixic acid | ∗∗ | ∗∗ | 6.1 |
| Norfloxacin | ∗∗ | ∗∗ | 18.2 |
| ESBL production | 8.8 (3/34) | 34.8 (8/23) | 21.2 (7/33) |
| Carbapenem resistance | 50 (17/34) | 38.8 (8/23) | 36.4 (12/33) |
∗∗Not tested as these are not indicated for the treatment of selected infections.